Tirzepatide

Description

Tirzepatide is a synthetic peptide engineered to act as a dual agonist of the glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors. This novel incretin mimetic is under investigation for its role in modulating glucose metabolism and energy balance, making it a focal point in current metabolic disease research.

Structurally based on a 39-amino-acid sequence, tirzepatide incorporates both non-natural amino acids and fatty acid side chains to enhance stability and pharmacokinetic profile. This allows for once-weekly administration in clinical contexts. Its unique dual-receptor activity distinguishes it from mono-agonists such as semaglutide or liraglutide.

Applications:
This peptide is intended for use in preclinical studies, receptor binding assays, mechanistic evaluations, and metabolic pathway elucidation. It is not for human consumption, therapeutic use, or diagnostic procedures.

Key Research Areas:

• Type 2 diabetes and insulin resistance
• Obesity and weight regulation pathways
• GIP and GLP-1 receptor pharmacodynamics
• Appetite suppression mechanisms